Home > Insider Trading > Filing (0000950170-24-026001)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1787400	Nkarta Inc.	NKTX	Pharmaceutical Preparations (2834)	474515206

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1853197	Ralph Brandenberger	C/O Nkarta, Inc. 1150 Veterans Boulevard South San Francisco CA 94080	Chief Technical Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-03-01	3,808	$3.89	85,384	No	4	M	Direct
Common Stock	Acquisiton	2024-03-01	2,955	$3.89	88,339	No	4	M	Direct
Common Stock	Disposition	2024-03-01	8,367	$12.51	79,972	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2024-03-01	3,808	$0.00	3,808	$3.89
Common Stock	Stock Option (right to buy)	Disposition	2024-03-01	2,955	$0.00	2,955	$3.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,445		2029-09-05	No	4	M	Direct
25,629		2029-09-05	No	4	M	Direct

Footnotes

The transaction reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person and most recently amended on September 2, 2022.
This transaction was executed in multiple trades at prices ranging from $12.50 to $12.58. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
The options exercised were fully vested.
The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on July 1, 2024.